SNG vs. OBI, NSCI, BVX, IMM, OPTI, DEST, ONC, OBD, SAR, and GENF
Should you be buying Synairgen stock or one of its competitors? The main competitors of Synairgen include Ondine Biomedical (OBI), NetScientific (NSCI), BiVictriX Therapeutics (BVX), ImmuPharma (IMM), OptiBiotix Health (OPTI), Destiny Pharma (DEST), Oncimmune (ONC), Oxford BioDynamics (OBD), Sareum (SAR), and Genflow Biosciences (GENF). These companies are all part of the "biotechnology" industry.
Synairgen (LON:SNG) and Ondine Biomedical (LON:OBI) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, community ranking, media sentiment, valuation and risk.
28.6% of Synairgen shares are owned by institutional investors. Comparatively, 9.2% of Ondine Biomedical shares are owned by institutional investors. 3.1% of Synairgen shares are owned by company insiders. Comparatively, 61.5% of Ondine Biomedical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Synairgen received 152 more outperform votes than Ondine Biomedical when rated by MarketBeat users. However, 100.00% of users gave Ondine Biomedical an outperform vote while only 56.46% of users gave Synairgen an outperform vote.
In the previous week, Synairgen and Synairgen both had 1 articles in the media. Synairgen's average media sentiment score of 0.00 equaled Ondine Biomedical'saverage media sentiment score.
Synairgen's return on equity of -48.86% beat Ondine Biomedical's return on equity.
Ondine Biomedical has higher revenue and earnings than Synairgen. Ondine Biomedical is trading at a lower price-to-earnings ratio than Synairgen, indicating that it is currently the more affordable of the two stocks.
Synairgen has a beta of -2.23, suggesting that its share price is 323% less volatile than the S&P 500. Comparatively, Ondine Biomedical has a beta of -0.15, suggesting that its share price is 115% less volatile than the S&P 500.
Summary
Synairgen beats Ondine Biomedical on 7 of the 12 factors compared between the two stocks.
Get Synairgen News Delivered to You Automatically
Sign up to receive the latest news and ratings for SNG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SNG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Synairgen Competitors List
Related Companies and Tools
